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Background: No previous studies have examined the effect of intensive exercise in systemic sclerosis patients with
pulmonary impairment. The objective of this study was to examine the effect of an eight-week intensive aerobic
exercise and muscle endurance training program for patients with systemic sclerosis with 50–100% of forced vital
capacity.
Methods: A single-subject experimental design with repeated systematic measures during a six week A-phase
(non-interventional baseline period) and an eight week B-phase (exercise intervention period) was used. Three
women and one man with median age 66 years and median disease duration of 3.5 years completed aerobic
exercise corresponding to 15 on the Borg RPE scale (strenuous) and muscular endurance training three times/week.
Physical capacity (six-minute walk test), aerobic capacity (submaximal treadmill test) and muscle endurance in
shoulder and hip flexion (Functional Index 2) were assessed every other week throughout the 14-week study.
Activity limitation (Health Assessment Questionnaire), quality of life (Short Form 36), Raynaud, Fatigue and Global
Health during the recent week (Visual Analogue Scales) were assessed at weeks 0, 6, 14.
Results: Three participants improved significantly in muscular endurance, and two participants improved
significantly or clinically relevant in aerobic capacity. All other variables remained unchanged, except for a trend
towards reduced fatigue.
Conclusions: This eight week exercise program was largely successful with positive effects on aerobic capacity and
muscle endurance.
Trial registration: Clinicaltrials.gov Identifier: NCT01813578
Keywords: Systemic sclerosis, Physical exercise, Rehabilitation, Aerobic capacity, Interstitial lung diseaseBackground
Systemic sclerosis (SSc) is an uncommon autoimmune
systemic disorder presenting with skin fibrosis and vas-
culopathy and involving several different organ systems.
Based on the degree of skin involvement, the disease is
subdivided into limited cutaneous SSc (lcSSc) or dif-
fuse cutaneous SSc (dcSSc). Aside from skin fibrosis,
Raynaud’s phenomena and gastrointestinal involvement
are the most common disease manifestations [1].
Interstitial lung disease (ILD) is common, especially in
dcSSc, and along with pulmonary hypertension is the* Correspondence: helene.alexanderson@karolinska.se
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distribution, and reproduction in any mediummain cause of death in these patients [2]. Cardiopulmonal
involvement, when present, leads to shortness of breath
and reduced aerobic capacity [3]. In addition, arthralgia
and arthritis are common problems and patients often ex-
perience reduced muscle endurance and fatigability [4].
Individuals have self-reported reduced physical function
[5,6] and poorer quality of life compared to the general
population [7-9].
So far, only four studies have evaluated different exer-
cise regimens in SSc. All indicate the safety of exercise
with reduced disability. One study reported significantly
improved aerobic capacity in a group of seven patients
with SSc without lung involvement and seven healthy
controls following eight weeks of intensive aerobic exer-
cise [10]. An open study of 12 patients with SSc without
ILD reported improved muscle strength following anentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Table 1 Fatigue, Raynaud’s phenomenon, patients’ global
assessment of disease and perceived health assessed by
the SF-36 in the 4 participants
Participants 1 2 3 4
Assessment time points 0w 0w 0w 0w
Fatigue, VAS, 0-100 72 50 83 4
Raynaud, VAS, 0-100 56 55 60 50
Patient’s Global, VAS, 0-100 46 51 33 35
HAQ, 0-3 0.50 0.13 0.50 0.50
SF-36, 0-100
Physical functioning 60 45 30 60
Role physical 0 0 100 100
Bodily pain 22 100 41 62
General health 50 35 15 67
Vitality 25 60 15 85
Social functioning 25 100 75 75
Role emotional 33 33 100 100
Mental health 64 72 60 92
0w = first assessment time point of the A-phase.
6w = last assessment time point of the A-phase, right before starting exercise.
14w = last assessment point of the B-phase, after completion of the 8 weeks
of exercise.
VAS = visual analogue scale.
HAQ = Stanford Health Assessment Questionnaire.
SF-36 = Short Form 36.
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in 12 patients with SSc without ILD [11]. A randomized
controlled trial involving 20 patients with SSc evaluated
the effects of a rehabilitation program with manual tech-
niques such as massage and joint mobilization in combin-
ation with aquatic training, including walking, stretching
and breathing exercises performed twice a week for nine
weeks [12]. Patients with some degree of lung involvement
were included in both groups. The treatment group im-
proved significantly in self-reported quality of life and
activity limitation [12]. An individualized rehabilitation
program was evaluated involving 16 patients of whom
seven had lung fibrosis [13]. The group performed breath-
ing exercises, aerobic exercise on a treadmill or outdoor
walks, and 10 individual rehabilitation sessions during a
two-week period. Patients were then instructed to per-
form a home exercise program during the four-month
follow-up period. After four months, the exercise group
had improved in self-reported quality of life and hand
functions, and had reduced exercise heart rates and low-
ered perceived exertions during the six-minute walking
test while the non-randomized control group remained
unchanged [13].
Today evidence for the safety and efficacy of aerobic
and resistance training in patients with other inflamma-
tory diseases supports the inclusion of exercise as an im-
portant part of the treatment of these patients [14,15].
Further, aerobic exercise has been reported to improve
walking distance and quality of life as well as to reduce
dyspnea in patients with ILD [16]. So far evidence for
safety and effects of exercise in patients with SSc is lim-
ited, especially regarding intensive training.
The aim of this study was to evaluate the effects of
eight weeks of intensive aerobic exercise and muscle en-
durance training regarding walking ability, muscle func-
tion, aerobic capacity, limitations in daily activities and
quality of life in patients with limited or diffuse SSc with
50–100% of vital capacity.
Methods
Patients were recruited to this present study from an on-
going screening study for cardiovascular disease in SSc
at the Rheumatology clinic at Karolinska University Hos-
pital, Stockholm, Sweden. Medical charts were reviewed
and all patients fulfilling the criteria were invited to
participate in this exercise study (n = 15). The inclusion
criteria were; limited or diffuse SSc, age 18–80 years,
diagnosis duration ≥ 1 year, unchanged medication for 3
months, 50–100% of normal vital capacity, exercising ≤
once a week, Swedish language fluency, average or below
aerobic capacity according to the submaximal treadmill
test (≤ 27 ml/kg × min for women and ≤ 30 ml/kg × min
for men) [17], ≤ 20% reduced muscle endurance accord-
ing to the Functional Index-2. The exclusion criteria;Cyclophosphamide treatment for alveolitis, Pulmonal ar-
terial hypertension (PAH), heart condition contraindicating
exercise, < 50% of normal vital capacity, reduced kidney
function. Eleven patients declined participation, due to lack
of time in 10 cases, and a long trip abroad in one case.
Thus, four patients participated, three women and one
man with a median age of 66.5 years, ranging from (41–69)
years old with a median 3.5 range (2–5) years diagnosis
duration. Demographic data are presented in Table 1. Two
participants had lung fibrosis, participant 1 and 2, with 50
and 80% of forced vital capacity (FVC), respectively, while
the other two had 100% FVC. Two were treated with low
dose of oral corticosteroids, one with mycophenolate mofe-
til, and another one with statins. One was further treated
with estrogen and bronchial dilation. None of the partici-
pants exercised during the six months preceding inclusion
in the study, but three patients took ordinary walks 3–14
times per week. One was not physically active at all. They
had all retired from working life.
Demographic data such as age, gender, time of diagno-
sis, other diseases, medication, work, and ongoing physical
therapy/exercise, as well as level of physical activity were
registered in a questionnaire before the study started.
The six minute walk test (6MWT) was the primary out-
come [18,19]. The participants were instructed to walk as
far as possible at their pace of choice for six minutes and
to stop and rest when needed. Heart rate, saturation, and
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Borg CR-10 scale (0–10) [20] were recorded before start-
ing the test at rest and after 2, 4, and 6 minutes of walking.
The participants were asked to rate general exertion ac-
cording to the Borg RPE-scale (6–20) [21] at the comple-
tion of the test.
A submaximal treadmill test was used to estimate oxy-
gen uptake in ml/kg × min [17]. The test requires a total
of eight minutes where the first four minutes are per-
formed on a horizontal treadmill with the participant
walking at a self-selected walking speed. During the fol-
lowing four minutes, the patient continues at the same
walking speed on a 5% incline. Working heart rate, sat-
uration, and central and peripheral exertion according to
the Borg RPE 6–20 scale [21] were recorded every other
minutes and after completion of the test.
The number of correctly performed repetitions of the
shoulder and hip flexion tasks included in the Functional
Index 2 [22] was recorded as a measure of muscle en-
durance. Maximal numbers of repetitions are 60 for both
tasks, representing no limitations. After completing each
task, the perceived muscle exertion was recorded ac-
cording to the Borg CR-10 scale [20].
A Visual Analogue Scale (VAS) of 0–100 was used to
assess patients’ perceptions of Raynaud’s phenomenon,
global fatigue and global disease impact on well-being
during the last week [23].
The Stanford Health Assessment Questionnaire – HAQ
was used to assess activity limitation [24]. The HAQ com-
prises 20 items divided into eight categories; dressing and
grooming, arising, eating, walking, hygiene, reach, grip
and other activity. The HAQ score varies from 0–3, where
0 indicates no limitation.
The SF-36 was used to assess perceived health compris-
ing 36 items divided into eight domains; physical function-
ing, role physical, bodily pain, general health, vitality,
social functioning, role emotional, and mental health [25].
Each domain is scored separately between 0–100, where
100 indicates good health.
As SSc is a rare condition, a Single Subject Experimen-
tal Design (SSED) was used where each participant is his
or hers own control. According to an AB SSED, measures
producing quote data (six-minute walking test, the tread-
mill test for estimated oxygen uptake and the muscle en-
durance test FI-2) were systematically performed during
the four-week non-interventional A-phase and the follow-
ing eight-week interventional B-phase [26]. Measures pro-
ducing ordinal data (VAS), the HAQ and the SF-36 were
performed at 0, 6 and 14 weeks.
All clinical assessments were performed by one trained
physical therapist who was not involved in the exercise
intervention.
The exercise program contained aerobic exercise on a
stationary bike and muscular endurance training of theshoulder flexors and the hip flexors. The program started
with a 10-minute warm-up biking session at an intensity
corresponding to perceived light exertion (10 on the Borg
RPE, 6–20 scale) [21]. Afterward, the load was increased
to reach an intensity corresponding to perceived heavy ex-
ertion (15 on the Borg RPE scale) for an additional 15 mi-
nutes. During the last five minutes of the biking session,
the loads were reduced to an intensity corresponding to
light exertion. Heart rate was recorded with a pulse watch
(RS100 Polar) and peripheral saturation was recorded with
a heart rate oxymeter (Wristox 3100 Nonin Medical) dur-
ing the biking exercise part of the program. During the
first week, patients performed only the 10-minute warm-
up exercise and the following week another 5 minutes
were added with an intensity corresponding to somewhat
exerting (13 on the Borg RPE scale). During the remaining
six weeks, patients exercised with a goal intensity corre-
sponding to perceived heavy exertion (15 on the Borg RPE
scale) for a maximum of 30 minutes. After the biking ex-
ercises, the participants performed repetitive dynamic
muscle resistance training with the goal of achieving as
many shoulder flexion repetitions as possible in a sitting
position without back support with a 1-kg weight cuff
around the wrist, and in hip flexion, lifting one leg at a
time while lying in a supine position. The numbers of rep-
etitions were based on the results of the FI-2 tests for
these muscle groups. If participants at some point during
the exercise period performed the maximal number of
repetitions (60) of shoulder flexion, a heavier cuff was
attached to the wrist to increase the load. In case of per-
forming maximal repetitions of hip flexion, a weight cuff
of 0.5 – 1.0 kg was attached to the ankle. Every other
week, the numbers of repetitions were adapted according
to the results of the every other week systematic assess-
ments. During the first two weeks, patients performed
only 50% of the maximal number of repetitions performed
at the 0-week assessment and then gradually increased to
perform the maximal number of repetitions at each exer-
cise session. The participants exercised three times a week
under the supervision of a trained physical therapist at the
Department of Physical Therapy. To enhance compliance,
participants were given the choice to exercise at home or
at a gym twice a week and once a week under supervision
at the hospital.
According to the 2-standard deviation (2 SD) band
analysis, statistical analyses were performed for each pa-
tient individually [27]. Accordingly, a statistically signifi-
cant change was defined as two consecutive assessments
in the B-phase exceeding the two standard deviations
(SD) of the mean of the A-phase. To improve the internal
and external validity, analysis from more than one partici-
pant needs to be performed [26,27]. Measures producing
quote data are presented individually as mean and 2 SD
for the A-phase and as actual values from each assessment
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data are presented individually and were analyzed using
graphically identified trends or slope [26]. Where a trend
was identified, the Friedman’s ANOVA was used. The stat-
istical significance level was set to p < 0.05. The Statistica
10.0 was used. Patients were also analyzed according to
responder criteria. Participants improving ≥ 20% in walk-
ing distance, aerobic capacity and/or muscle endurance
compared to the A-phase mean value were considered
as a responder [28]. This study was approved by the
Karolinska University Hospital Research Ethics Com-
mittee and all participants signed informed consent
forms before entering the study.
Results
Three of the four participants (2, 3 and 4) completed all
24 exercise sessions as planned while participant 1 com-
pleted 22 sessions, missing two due to medical investiga-
tions of increased lung symptoms.
Participant 1 fulfilled all the inclusion criteria before en-
tering the study, however the participant was unable to in-
crease exercise intensity three weeks into the B-phase due
to increased dyspnea and cough during exercise. New lung
screening revealed increased bronchial obstructivity and
increased lung fluid. After initiating diuretic and bronchial
dilating treatment, the patient was cleared to continue the
exercise program, though remaining on the intensity of
the somewhat exerting exercise initiated at week three (13
on the Borg RPE). Two months after completing theTable 2 A-phase mean and 2SD, (mean + 2SD), and B-phase a
participant (1,2,3,4)
1 2
A mean ± 2SD (mean + 2SD) A mean ± 2SD (mean +
B weeks B weeks
8 10 12 14 8 10 12
6MWT, m 527 ± 64 (591) 429 ± 59 (488)
510 543 484 537 455 392 423
Treadmill, 31.7 ± 5.8 (37.5) α
ml/kg x min 30.0 27.0 30.0 29.0 23.0 21.4 23.0 2
FI-2, SF, R 10 ± 5.4 (15.4) 13.3 ± 4 (17.3)
Repetitions 9 7 10 10 16 16 17
FI-2, SF, L 9.5 ± 2 (11.5, 7.5) ¤ 12.3 ± 1 (13.3)
Repetitions 5 5 7 7 13 15 16
FI-2 HF, R 7.8 ± 4.1 (11.9) 19.5 ± 1.2 (21.7)
Repetitions 6 5 7 7 28 25 33
FI-2, HF, L 8.5 ± 3.9 (12.4) 18.9 ± 4.4 (23.3)
Repetitions 7 6 3 8 25 25 30
A = non-interventional A-phase, 2SD = 2 standard deviations from the mean, B = int
SF = Shoulder flexion, HF = Hip flexion, R = Right side, L = Left side, α = participant co
2 consecutive assessments in the B-phase exceed the mean + 2SD in the A-phase in
sessments in the B-phase exceed the mean - 2SD in the A-phase indicating a statist
mean of the A-phase.exercise program, another lung screening revealed in-
creased pulmonary disease activity along with increased
skin symptoms. The diagnosis was changed from limited
to diffuse SSc. Participant 2 was not able to complete the
treadmill test during the A-phase assessments due to
demonstrating maximal dyspnea, but was then able to
complete the test during all B-phase assessments. Partici-
pant 3 had reduced postural control and reduced distal
tactility of the lower limbs due to lumbar nerve impinge-
ment. Participant 3 was not able to perform the aerobic
exercise due to intense radiating pain in the lower limbs
after just one or two minutes of biking, but performed all
aerobic exercise sessions on a treadmill, setting the exer-
cise intensity according to the same perceived exertion
protocol as the other participants. Participant 4 had fluc-
tuating ankle arthritis pain which had been treated with
corticosteroid injections four months before entering the
study with sub-optimal results. This participant reached
the maximal number of repetitions of shoulder flexion
already during the A-phase and thus had no potential
for improvement in this test. However, the patient was
able to perform the 60 repetitions with 2 kg weights at
the end of the study.
Individual results of all variables are presented in Table 2.
After eight weeks of exercise, no participant showed a sta-
tistically significant change in physical walking distance
during the 6MWT. Participant 2 improved significantly in
shoulder flexion muscle endurance (Figure 1a) while par-
ticipants 2 and 3 improved significantly in hip flexionssessment points presented individually for each
3 4
2SD) A mean ± 2SD (mean + 2SD) A mean ± 2SD (mean + 2SD)
B weeks B weeks
14 8 10 12 14 8 10 12 14
384 ± 73 (457) 406 ± 23 (429)
450 390 390 394 407 421 424 390 420
21.9 ± 0.7 (22.6) 31.4 ± 1.5 (32.9)
4.3# 22.2 24.3 24.1 23.8* 30.9 31.0 31.5 31.2
22.3 ± 4.8 (27.1) 60 ± 0 (60)
29# 24 21 25 28# 60 60 60 60
19.5 ± 6.2 (25.7) 60 ± 0 (60)
25*# 25 23 30 25# 60 60 60 60
13.3 ± 7.2 (20.5) 37.3 ± 25.4 (62.7)
45*# 16 18 31 34*# 50 60 60 60#
13.0 ± 5.4 (18.4) 35.5 ± 21.3 (56.8)
45*# 11 15 28 25*# 48 60 60 60*#
erventional B-phase, 6MWT = 6-minute walking test, FI-2 = Functional Index-2,
uld not complete any of the A-phase assessments due to exertion, * = at least
dicating a statistically significant improvement, ¤ = at least 2 consecutive as-
ically significant worsening, # = responder improving ≥ 20% compared to the
Participant 2























































































































































































































Figure 1 Individual results of muscle endurance assessed by the FI-2 in participants 2 and 3 (1a-1e), and aerobic capacity in participant
3 (1f).
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proved ≥20% in shoulder flexion muscle endurance bilat-
erally and participants 2, 3 and 4 improved in hip flexion
bilaterally, according to criteria [29]. Participant 1 wors-
ened significantly, but not ≥ 20%, in shoulder flexion, leftside (Table 2). Participant 3 improved significantly in aer-
obic capacity assessed by the treadmill test after the eight-
week exercise program (Figure 1f, Table 2). Participant 2
was not able to complete the test at any of the four A-
phase assessment time points, enabling calculations of
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all treadmill tests during the B-phase (Table 2).
By visual graph analysis for trend and slope, a trend
towards reduced fatigue was identified in participants 2,
3, and 4 assessed by the VAS which was also supported
by an almost statistically significant reduction in fatigue
(p = 0.056) (Figure 2). There was no visually identified
trend or slope regarding Raynaud’s phenomenon or glo-
bal disease impact on well-being assessed by the VAS, or
activity limitations assessed by the HAQ.
Discussion
Four participants with SSc and with 54–100% of max-
imal vital capacity participated in an eight week intensive
aerobic and muscle endurance exercise program. Three
participants improved their muscle endurance and two
participants improved their estimated oxygen uptake.
There were no changes in physical capacity, limitations
in daily activities, quality of life, Raynaud’s phenomenon
or global disease impact on well-being, although there
was a trend toward reduced fatigue following the exer-
cise program.
There was no change in the primary outcome physical
capacity measure 6MWT in any of the patients as there
were large variations in individual walking distances dur-
ing both the A- and the B-phase. Studies have pointed
out that lower-extremity joint or muscle-oriented pain,
as well as central and peripheral exertion also could re-
duce the walking distance [29,30]. This was the case with
participants 3 and 4 in our study, who had fluctuating
arthritis of the ankles and reduced balance and tactility of



























Figure 2 Individual results of patient-reported fatigue assessed by thParticipant 2 was unable to complete the treadmill test
during the A-phase assessments, making it impossible to
calculate an A-phase mean and 2 SD. However, as this
participant was able to complete all tests during the B-
phase, this was interpreted as a clinically relevant im-
provement. Since most participants performed the aerobic
exercise on a stationary bike, it would probably have been
better to perform the estimated oxygen uptake test on a
bike. However, prior clinical experience suggested that
lower limb muscle fatigue might hamper patients’ ability
to complete a submaximal oxygen uptake biking test. Fur-
ther research is needed to find a valid and feasible method
to measure aerobic capacity and physical capacity in SSc
and when using the 6MWT in clinical practice and re-
search in these patients, a careful consideration of its
measurement properties is important.
There was also a within-patient variation in muscle en-
durance in different tasks of the FI-2. Participants 2 and 3
improved significantly in either shoulder flexion or hip
flexion. Participant 4 had a large variation in numbers of
repetitions in the right hip flexion task, producing a wide
2SD-band. Although the participant performed clinically
relevant more repetitions during assessments in the B-
phase compared to the mean value of assessments in the
A-phase, the wide 2SD-band prevented this change from
reaching statistical significance. Although reaching the
maximal number of repetitions of shoulder flexion dur-
ing the A-phase, this participant was able to increase
the training load from 1 to 2 kg suggesting increased
muscle endurance.
The visual plot analysis revealed a trend toward reduced
fatigue in three participants. Fatigue is one of the mosteeks 14 weeks
_   _____B-phase_______
e VAS, 0–100.
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exercise might be an effective treatment to reduce fatigue
and this should be a prioritized research area in the future.
Four months prior to entering the study, participant 1
had stopped the treatment with mycophenolate mofetil,
which is the most probable explanation for the increased
lung symptoms present in the beginning of the B-phase.
As the participant had exercised with a similarly inten-
sive program about a year before entering the study, and
while participating in this study never reached the inten-
sive exercise equivalent with perceived exertion of 15 on
the Borg scale, it is not likely that the exercise program
contributed to increased lung symptoms. This is supported
by studies reporting the safety of other inflammatory sys-
temic conditions such as myositis and SLE [15,31] and
prior studies reporting the safety of moderate exercise in-
tensity in SSc with lung fibrosis [12,13]. Participant 1, with
the most severe lung involvement, did not improve, while
the participant 2, with slightly milder lung fibrosis, did im-
prove in both aerobic capacity and muscle endurance. This
might emphasize the importance of optimal medical treat-
ment to achieve the positive effects of exercise in patients
with SSc and lung fibrosis. Due to differences in study pop-
ulations, numbers of participants, exercise programs and
climates it is difficult to compare our results with prior
studies evaluating exercise in SSc. Our study was con-
ducted during the winter or early spring when patients
with SSc usually experience more Raynaud’s phenomenon
[32]. Since no participant in our study experienced in-
creased Raynaud’s phenomenon, this might in fact be an
effect of the exercise. Our results confirm previous reports
of intensive exercise in SSc without lung fibrosis leading to
improved or unchanged aerobic capacity, improved muscle
function or the absence of improvements in quality of life
assessments and adverse events (10, 11). However, our
study is the first to reveal data indicating that exercise
might reduce fatigue in SSc.
All patients were familiar with the objective and the
self-reported measures included in this study as they are
all used in standard clinical follow-ups as well as in the
ongoing screening study at the Rheumatology clinic,
Karolinska.
A SSED was used for this study as we predicted difficul-
ties in recruiting enough patients for a randomized
controlled trial (RCT). As a statistical analysis can be per-
formed for each individual, a SSED could have higher
validity compared to an open-label group analysis since
similar improvements were achieved among three of the
participants [27,28]. Using the ABA-design, also including
a new non–interventional A-phase following the B-phase,
would have further strengthened our study. Following rec-
ommendations from the regional ethical committee, the
AB-design was used as it might be unethical to ask pa-
tients to discontinue a potentially effective treatment.Physical tests were performed every other week to avoid
training effects during the A-phase. The variation in phys-
ical capacity was probably due to day-to-day variations
and the changes in temperature and humidity. Our ex-
perience with using a SSED in an exercise pilot study in-
volving patients with polymyositis and dermatomyositis
revealed less day-to-day variations producing smaller 2
SD-bands [33]; this type of design has also been used
successfully in an exercise study in SLE [31].
Exercise intensity was set according to participants’ sub-
jective ratings of exertion using the Borg RPE scale, which
is a limitation as there might be individual differences in
the perception of perceived exertion [21].
Only four participants were included, limiting the exter-
nal validity of the study with the majority who chose not to
participate being younger and still working. As fatigue is a
common symptom (6), maybe they did not have the energy
to include a 3-days-a-week exercise program in their daily
lives. Perhaps a home-based exercise program would be
easier to incorporate into daily life. As all the participants
were registered at a university hospital, they might have
had a more severe disease course than the general popula-
tion with SSc. However, both types of diagnosis were repre-
sented, and the three women and one man included could
be representative as the majority of individuals with SSc
are women [4]. To achieve solid evaluation of the safety
and efficacy of exercise in SSc, larger multi-center RCTs
are needed. There is an ongoing effort to establish a core
set of measures to be used in SSc which would enhance
these kinds of studies [34].
Conclusions
In conclusion, this eight week aerobic and muscle endur-
ance exercise program was overall beneficial, resulting in
improved aerobic capacity and muscle endurance in two
out of four participants. There were no changes in the
primary outcome 6MWT or in the patient reported out-
comes, although there was a trend towards reduced fa-
tigue. There is a need for a large multi-center RCT, also
including patients with various degree of lung involvement
to further establish evidence of exercise effects in SSc.
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